Skip to main content

Table 2 Further subgroup analysis and sensitivity analyses on primary outcome of mortality rate

From: Terlipressin for septic shock patients: a meta-analysis of randomized controlled study

  Groups References Patient number (TP/Ctrl) Event (TP/Ctrl) RR (95%CI) I 2 P
Subgroup analyses
 Type of control NE [2, 8,9,10, 13, 21,22,23] 425/413 200/202 0.95 (0.85,1.06) 0% 0.33
DA [14, 20] 46/44 27/28 0.92 (0.67,1.26) 0% 0.61
 Published year After 2010 [2, 5, 20,21,22,23] 377/384 169/182 0.95 (0.84,1.07) 8% 0.40
Before 2010 [9, 10, 13, 14] 94/73 58/48 0.92 (0.74,1.16) 0% 0.49
 Study designed Blinded [8, 21] 275/283 109/114 0.73 (0.31,1.72) 79% 0.48
Unblinded [2, 9, 10, 13, 14, 20, 22, 23] 196/174 118/116 0.93 (0.83,1.05) 0% 0.24
 TP dose < 2 mg/d [9, 10, 13, 22] 95/71 47/36 0.92 (0.69,1.22) 0% 0.55
2–4 mg/d [2, 8, 14, 20, 21] 334/344 148/158 0.96 (0.82,1.12) 0% 0.61
> 4 mg/d [23] 42/42 32/36 0.89 (0.72,1.10) 0.27
 Administration route Bolus [9, 13, 21] 64/47 36/31 0.81 (0.46,1.40) 51% 0.44
Continuous infusion [2, 8, 10, 14, 20, 22, 23] 407/410 191/199 0.96 (0.86,1.07) 0% 0.42
Sensitivity analyses
  28-day mortality [2, 20, 22, 23] 102/101 60/68 0.93 (0.81,1.07) 0% 0.34
ICU mortality [9, 10, 14] 84/63 53/44 0.91 (0.72,1.14) 0% 0.41
Hospital mortality [13] 10/10 5/4 1.25 (0.4,3.33) 0.66
90-day mortality [2] 13/17 12/16 0.98 (0.81,1.19) 0.85
More severe septic shock [2, 9, 10, 13, 14] 107/90 70/64 0.96 (0.82,1.11) 0% 0.55
Less severe septic shock [8, 20,21,22,23] 364/367 157/166 0.72 (0.40,1.29) 43% 0.14
Exclusion of the largest trial [2, 9, 10, 13, 14, 20,21,22,23] 211/191 123/129 0.91 (0.81,1.03) 0% 0.14
Exclusion of pediatric patients [2, 8,9,10, 13, 20,21,22,23] 441/429 207/210 0.95 (0.85,1.05) 0% 0.31
  1. Ctrl control group, DA dopamine, ICU intensive care unit, NE norepinephrine, RR risk ratio, TP terlipressin group
Back to article page